178 related articles for article (PubMed ID: 10605187)
1. [The other side of the coin: socioeconomic analysis of antibiotic resistance].
García-Altés A; Jovell AJ; Aymerich M
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():27-31. PubMed ID: 10605187
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of resistance in the community.
Eandi M; Zara GP
Int J Clin Pract Suppl; 1998 Jun; 95():27-38. PubMed ID: 9796553
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
4. Cost of Gram-negative resistance.
Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG
Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic impact of an antibiotics stewardship programme in a regional hospital in Hong Kong.
Ng CK; Wu TC; Chan WM; Leung YS; Li CK; Tsang DN; Leung GM
Qual Saf Health Care; 2008 Oct; 17(5):387-92. PubMed ID: 18842981
[TBL] [Abstract][Full Text] [Related]
6. Balancing the benefits and costs of antibiotic drugs: the TREAT model.
Leibovici L; Paul M; Andreassen S
Clin Microbiol Infect; 2010 Dec; 16(12):1736-9. PubMed ID: 20673259
[TBL] [Abstract][Full Text] [Related]
7. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Simoens S
Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
[TBL] [Abstract][Full Text] [Related]
8. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
Jackson J; Fernandes AW; Nelson W
Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
[TBL] [Abstract][Full Text] [Related]
9. Economics of antibiotic resistance.
Sipahi OR
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118
[TBL] [Abstract][Full Text] [Related]
10. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
11. The impact of antimicrobial resistance on health and economic outcomes.
Cosgrove SE; Carmeli Y
Clin Infect Dis; 2003 Jun; 36(11):1433-7. PubMed ID: 12766839
[TBL] [Abstract][Full Text] [Related]
12. Economic impact simulation analysis of use of tigecycline, as appropriate, in first-course antibiotic therapy for complicated intra-abdominal infections in intensive care patients.
Ancona F
Minerva Med; 2010 Oct; 101(5):319-28. PubMed ID: 21048554
[TBL] [Abstract][Full Text] [Related]
13. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
14. [Microbial resistance: what is to be done? Information from the panel of experts].
Mochales FB; Castelló RB; Marqués JC; Rodríguez LD; Alemany XG; Rodríguez JA; Beato EP; Gorricho BP; Trallero EP; Pastor GP
Rev Esp Salud Publica; 1995; 69(6):445-61. PubMed ID: 8789357
[TBL] [Abstract][Full Text] [Related]
15. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
Kusowska J
Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
[TBL] [Abstract][Full Text] [Related]
16. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
Kusowska J
Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
[TBL] [Abstract][Full Text] [Related]
17. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
Simoens S; Decramer M; Laekeman G
Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact and relevance of antibiotic resistance.
French GL
Adv Drug Deliv Rev; 2005 Jul; 57(10):1514-27. PubMed ID: 15978698
[TBL] [Abstract][Full Text] [Related]
19. Cost and quality considerations in antibiotic formulary management.
Ritchie DF
Pharm Pract Manag Q; 1996 Jul; 16(2):4-8. PubMed ID: 10161610
[TBL] [Abstract][Full Text] [Related]
20. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
Jarque I; Sanz MA
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
